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Abstract
Organophosphate poisoning is not uncommon in Taiwan. However, no case 
of intermediate syndrome (IMS) has been published. We report a case of 
delayed-onset IMS presenting with abrupt respiratory failure following the 
acute cholinergic crisis of phenthoate poisoning. Based on electrophysi-
ological studies from the literature, IMS results from an excess amount of 
acetylcholine at neuromuscular junction nicotinic acetylcholine receptors 
due to prolonged inhibition of acetylcholinesterase. This phenomenon leads 
to downregulation of the acetylcholine receptor and promotes muscle weak-
ness. There are still no appropriate parameters to predict the development 
of IMS. Perhaps electrophysiological studies can be applied in the future. 
Ventilatory support is the most important treatment; the benefits of pra-
lidoxime treatment are still controversial. IMS is still a challenging com-
plication of organophosphate poisoning. Physicians should not overlook 
IMS. [Tzu Chi Med J 2007;19(3):159–163]
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1. Introduction
Organophosphate (OP) pesticides are widely used in 
agriculture. OP poisoning is not uncommon in sui-
cidal patients in Taiwan because these pesticides 
are readily available from the market [1,2]. OP pes-
ticides are inhibitors of acetylcholinesterase (AChE). 
Emergency department (ED) physicians can recog-
nize a patient with possible OP poisoning by the 
typical cholinergic signs, including increased secre-
tions (bronchorrhea, salivation, tearing or sweating), 
bradycardia, vomiting and increased gastrointestinal 
motility (diarrhea or cramping), miosis, muscle fas-
ciculation and even coma resulting from severe 
exposure [3]. The ratio of death to total OP intoxica-
tion cases during 1985–1997 in Taiwan was 11.5% 
[4]. Relatively low incidences of mortality were found 
in both the USA and Taiwan in recent reports, and 
only low percentages of chronic sequelae devel-
oped in survivors [1,5]. Consequently, occasional 
life-threatening complications, e.g., abrupt respira-
tory failure due to intermediate syndrome (IMS), are 
sometimes overlooked. Here, we report a case of 
IMS in Taiwan.
2. Case report
A 56-year-old man suffering from unconsciousness 
with incontinence and vomiting was found by his 
family and immediately brought to the ED. Bilateral 
pin-point pupils, profuse salivation, muscle fascicula-
tion, and bilateral crackles on examination of breathing 
sounds were observed by ED physicians. OP poisoning 
was implicated by the clinical presentation. Atropine 
1 mg and pralidoxime 500 mg were quickly adminis-
tered. Intubation was performed due to dyspnea and 
airway protection. Subsequently, his family found half 
a bottle of phenthoate, an OP pesticide, and an empty 
bottle of rice wine in his room. Hence, OP poison-
ing was impressed. After primary management in the 
ED, the patient was transferred to the intensive care 
unit (ICU) for further management.
Initial levels of serum and red blood cell (RBC) 
AChE were 2 and 15 μM/sec/L, respectively (normal 
ranges, 20–61 and 20–46 μM/sec/L, respectively, at 
Tzu Chi General Hospital). In the ICU, the continuous 
infusion dosages of atropine (Atropair®) and pralidox-
ime (2-PAM®) were titrated according to the amount 
of secretion, muscle fasciculation and pupil size. An 
antimicrobial agent, ampicillin/sulbactam (Unasyn®), 
was administered for aspiration pneumonia based 
on pyrexia, leukocytosis (white blood cells [WBCs], 
29,200 cells/μL), left shifting (15% and 76% of band-
form and segment-form WBCs, respectively) and bila-
teral lower lung field infiltrations on chest X-ray. 
Pralidoxime was discontinued on the 3rd day of hospi-
talization after recovery of consciousness and muscle 
power. The endotracheal tube was also removed on 
the same day, and the patient was then supported by 
noninvasive positive pressure ventilation with bilevel 
positive airway pressure (BiPAP). Later, sputum culture 
revealed Klebsiella pneumonia and Pseudomonas 
aeruginosa. The antibiotic was then changed to cip-
rofloxacin. Only a few infiltrations over bilateral lung 
fields were observed in the following chest X-rays 
and no further fever was noted.
Unfortunately, sudden-onset irritability, dyspnea 
and carbon dioxide retention (PCO2 116.3 mmHg in 
arterial gas) developed on the 7th day of hospitaliza-
tion. The patient was re-intubated and pralidoxime 
was reinstated under suspicion of IMS. Follow-up RBC 
AChE had decreased to 2 μM/sec/L on the 8th day of 
hospitalization. Unexpected removal of the endotra-
cheal tube by the patient occurred on the 9th day of 
hospitalization. Intubation was reinstated 1 day later 
due to respiratory muscle fatigue. Administration of 
pralidoxime was continued until the 10th day of hospi-
talization. Subsequent RBC AChE activity was 23 μM/
sec/L on the 14th day of hospitalization. Ventilatory 
support was continued until the 15th day of hospital-
ization and weaning was successful this time. The 
patient was transferred to an ordinary ward on the 
16th day of hospitalization due to his stable condi-
tion. Atropine infusion was stopped on the 21st day 
of hospitalization and the patient was discharged 
on the 22nd day of hospitalization. The relationship 
between the level of RBC AChE and the clinical 
course is shown in Fig. 1.
3. Discussion
Neuromuscular weakness resulting from OP poisoning 
is divided into three types: (a) type I paralysis—muscle 
weakness occurring within the first admission day 
associated with cholinergic signs; (b) type II paraly-
sis or IMS—delayed muscle weakness occurring after 
the acute cholinergic phase of OP poisoning; (c) type 
III paralysis—polyneuropathy occurring 2–3 weeks 
after OP poisoning [6].
OP poison-induced IMS was first described in 1987 
[7]. IMS occurred after recovery from the acute cholin-
ergic crisis but before OP-induced delayed polyneu-
ropathy [8]. It is usually observed 12–72 hours after 
OP poisoning and may last up to 5–6 days [7]. This 
syndrome is characterized by sudden-onset muscle 
weakness, including the respiratory muscles (par-
ticularly the diaphragm), as well as paralysis of the 
neck muscles (inability to raise the head from the 
pillow) and weakness of proximal limb muscles [7]. 
Occasionally, certain cranial nerve palsies, such as 
the external ocular, jaw, facial and palatal muscles, 
may be observed [7]. Patients usually become anx-
ious due to rapidly progressive difficulty in breathing. 
Consciousness is not lost unless hypoxia or carbon 
dioxide retention exists [8]. Intubation and mechani-
cal ventilation is needed if respiratory failure occurs, 
and the duration of ventilatory care varies between 
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Fig. 1 — Red blood cell acetylcholinesterase (RBC AChE) 
activity and clinical course.
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7 and 21 days [8]. In our case, IMS developed on the 
7th day after OP poisoning. It seemed to be delayed 
more than the usual manifestation. However, no other 
conditions such as deterioration of pneumonia or 
sputum impaction could explain the sudden onset 
of respiratory failure. This delayed-onset IMS might 
result from the large amount of OP ingested and the 
OP being stored for longer in the patient’s body.
Leon et al [9] reviewed published insecticide intox-
ications between 1965 and 1995, and they found 
that IMS occurred in 20–68% of affected patients. 
However, no IMS cases from Taiwan have been reported 
on MEDLINE, and not even in a 633-case collection of 
OP poisoning by the National Taiwan Poison Control 
Center from 1985 to 1999 [10]. From our observa-
tions, we suppose that delayed extubation is usually 
chosen by Taiwan physicians if respiratory failure 
develops after OP poisoning. So, onset of IMS might 
overlap with the period of ventilator support. However, 
the mean duration of mechanical ventilation has not 
been recorded in previous studies in Taiwan [1]. 
Statistically, parathion was the causative agent of IMS 
in up to 75% of cases in previous studies [9]. Fenthion, 
dimethoate, monocrotophos, methamidophos and 
malathion were also reported to cause IMS [11,12] 
but no reported case developed IMS after phenthoate 
ingestion. In the World Health Organization (WHO) clas-
sification of OP pesticides, phenthoate and parathion 
are classified as class II-moderately hazardous and 
class Ia-extremely hazardous, respectively. The oral 
LD50 (LD: lethal dosage) in rats for phenthoate and 
parathion mentioned on the online material safety 
data sheet (MSDS) is > 600 mg/kg and 20–30 mg/kg, 
respectively. This information shows that the fewer 
phenthoate IMS cases might be due to its lower toxicity. 
This IMS case, caused by less hazardous phenthoate, 
might be due to the large amount of this OP that was 
ingested.
Electrophysiological studies may offer some hints 
regarding the development of IMS. Three phenomena 
of electrophysiological studies were observed in IMS: (a) 
repetitive firing following a single stimulus; (b) grad-
ual reduction in twitch height or compound mus cle 
action potential followed by an increase, with repeti-
tive stimulation of ≥ 20 Hz (decrement-increment res-
ponse); and (c) continued reduction in twitch height 
or compound muscle action potential with repetitive 
simulation (decrementing response) [13]. The decre-
menting response is the most frequent finding during 
IMS resulting from a marked downregulation of ace-
tylcholine receptors (AChRs) at the post-junctional 
membrane, along with a failure of the pre-junctional 
ACh mobilization receptor. Downregulation of AChRs 
is due to a compensatory response after prolonged 
exposure to ACh followed by decrease of AChRs result-
ing from endocytosis [14]. A pure decrementing res-
ponse has been observed at the highest levels of 
AChE inhibition [15]. Further, very weak AChE stain-
ing in skeletal muscle by immunohistochemistry was 
observed in a case of IMS [16]. In summary, IMS 
results from excess ACh at the neuromuscular junc-
tion nicotinic AChRs following prolonged inhibition 
of AChE. Although some clinical studies reported a 
positive correlation between IMS and electrophysi-
ological findings [17,18], more evidence from large 
numbers of clinical cases is required for verification.
Many physicians use serum or RBC AChE activity to 
monitor OP poisoning. Serum AChE, also called pseu-
docholinesterase or butyrylcholinesterase (BuChE), is 
found in the serum, liver, pancreas, heart and brain. 
It is subject to a high degree of variation influenced 
by many conditions, such as liver dysfunction, decom-
pensated heart disease, malnutrition, allergic disease 
and malignant neoplasm [3]. Further, no discernible 
difference in the serum AChE between day 1 and day 
3 after OP poisoning has been observed in IMS patients 
[19]. Hence, there is no predictive value of serum 
AChE for IMS. In contrast, RBC AChE is more reliable, 
with better correlation in terms of clinical presenta-
tions [20,21]. In this case, the nadir of RBC AChE was 
observed while IMS was developing. Increased RBC 
AChE was noted when the patient recovered from IMS 
and was successfully weaned off mechanical ventila-
tion. This observation fits in with the previous report 
that stated that clinical recovery correlates well with 
RBC AChE recovery to 30% of normal [22]. However, 
studies regarding RBC AChE level as a predictor of 
IMS should be conducted in the future.
The OP-AChE bond is not spontaneously reversible 
without pharmacological intervention [23]. AChE can 
be reactivated by oximes (e.g. pralidoxime) in vitro 
and in vivo [24,25], although the rate of reactivation 
may be affected by the dose of oxime administered 
and persistence of active OP in the body [26]. The dose 
and route of exposure, the chemical structure of the 
OP, the time to initiation of therapy, and possibly efforts 
to decrease absorption or enhance elimination of the 
OP are factors leading to prolonged cholinesterase 
inhibition [27]. A prospective study demonstrated the 
persistence of detectable OP in gastric juice several 
days after oral ingestion despite repeated lavage 
[28]. In addition, the structure of the OP may modify 
the efficacy of pralidoxime and influence the risk of 
prolonged cholinesterase inhibition [29]. Oxime was 
believed to be effective and necessary in treating OP 
poisoning. A bolus of 30 mg/kg of pralidoxime fol-
lowed by infusions of > 8 mg/kg/hr was suggested by 
WHO-sponsored recommendations [30]. However, 
there has been a paucity of controlled trials in humans. 
One meta-analysis demonstrated no statistically signif-
icant association between oxime therapy and mortal-
ity, ventilatory requirements or the incidence of IMS 
[31]. Sudakin et al [27] also reported a case of IMS 
after malathion ingestion despite continuous infusion 
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of pralidoxime. Therefore, the appropriate strategy 
for OP poisoning, especially when IMS occurs, should 
be further investigated. We still believe that oxime is 
a good candidate for IMS therapy but more prospec-
tive randomized controlled trials with appropriate 
patient stratification should be conducted. In addition, 
fresh frozen plasma (FFP), which contains BuChE, 
was thought to be an alternative strategy for IMS treat-
ment [32]. In this study, IMS developed in 28.6% of 
patients receiving pralidoxime treatment but no IMS 
case occurred with FFP transfusion. No cases of mor-
tality were reported in the FFP + atropine + pralidoxime 
group compared with 14.3% in the pralidoxime group. 
However, only 24 cases were enrolled in the study. 
Further randomized controlled research is required.
In summary, IMS might not be such an uncommon 
complication of OP poisoning. The few cases reported 
in Taiwan might be the result of physicians’ unaware-
ness. All physicians should keep in mind that IMS 
may occur following acute cholinergic crisis despite 
aggressive treatment. Ventilatory support is adequate 
but the use of pralidoxime is still controversial in the 
treatment of IMS. FFP may be considered as an alter-
native or adjuvant therapy. Prevention, prediction and 
treatment of IMS after OP poisoning is still a challenge, 
and further investigations should be carried out.
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